Companies/Ovation Science Inc.

Company profile

Ovation Science Inc.

OTC: OVATF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Vancouver, BCReports USD

#1068 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

23D

FH 19DQ —GM 31SS 28

v0.1 · 45/100 weight · provisional

↑ disclosure history, growth stability · ↓ balance-sheet leverage, return on assets

Methodology →

Revenue TTM

$47.6k

Rev growth YoY (TTM)

-27.0%

Net income (FY)

-$451.2k

Employees

Market cap

$1.3M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$48.5k67.8k CAD2025

Net income-$451.2k-630.7k CAD2025

Operating income-$427.6k-597.7k CAD2025

Total assets$60.4k82.8k CAD2025

Liabilities$1.1M1.5M CAD2025

Equity-$1.1M-1.5M CAD2025

Revenue trend

FY2018 – FY2025 · USD

$74.4k

FY18

$227.9k

FY19

$559.2k

FY20

$179.4k

FY21

$106.2k

FY22

$45.9k

FY23

$82.7k

FY24

$48.5k

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Ovation Science Inc. booked $48.5k in FY2025 revenue, contracting 41% year over year — slower than 80% of Healthcare companies we track, at a -929.9% net margin.

Peers · Healthcare

Nu-Med Plus, Inc.23D Dogecoin Cash, Inc.39D Bespoke Extracts, Inc.——AXIM Biotechnologies, Inc.——

Key facts

CEOTerry H. Howlett

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersVancouver, BC

ExchangeOTC: OVATF

Employees5

IPO date2019-01-29

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.